Live Breaking News & Updates on Regulatory preparedness

Stay informed with the latest breaking news from Regulatory preparedness on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Regulatory preparedness and stay connected to the pulse of your community

Fake COVID-19 Vaccines Now in Nigeria, NAFDAC Alert

•Global deaths surpass 2 million
Onyebuchi Ezigbo in Abuja
The National Agency for Food and Drug Administration and Control (NAFDAC) yesterday said it has reports of the importation of fake COVID-19 vaccines into Nigeria.
Addressing a virtual press conference, the Director General of the agency, Prof Mojisola Christianah Adeyeye pleaded with Nigerians to avoid the fake vaccines, saying, “they can cause Covid-like illnesses or other serious diseases that could kill.”
She said the agency had not received any application from Covid vaccine manufacturers yet and therefore no vaccines had been approved by NAFDAC.
“Covid-19 vaccines are new, and the side effects or adverse effects must be well monitored, therefore, if NAFDAC does not approve, the public should not use,” the NAFDAC boss said.

Nigeria , Lagos , Ikeja , Abayomi , Nigeria-general , Abuja , Abuja-federal-capital-territory , Lagos-state , Nigerians , Antonio-guterres , Onyebuchi-ezigbo , Mojisola-christianah-adeyeye

Nigeria warns of reported fake COVID-19 vaccines

National Agency for Food and Drug Administration and Control pleads with public to be aware

Nigeria , Abuja-federal-capital-territory , China , Italy , Wuhan , Hubei , Federal-capital-territory , Nigerian , Johns-hopkins-university , Nigeria-centre-for-disease-control , National-agency-for-food

COVID-19: NAFDAC debunks rumours on approval of vaccine

Share
The National Agency for Food and Drug Administration and Control (NAFDAC) has said it has not received any application from Covid Vaccine manufacturer and therefore no vaccines have been approved by the Agency.
This was disclosed on Friday by the Director-General of the Agency, Prof. Mojisola Adeyeye at a virtual media briefing in Abuja.
Adeyeye said there are reports of fake vaccines in Nigeria, pleading with the public to beware as no COVID-19 vaccines have been approved by the Agency and fake vaccines can cause Covid-like illnesses or other serious diseases that could kill.
“Covid-19 vaccines are new, and the side effects or adverse events must be well monitored, therefore, if NAFDAC does not approve, the public should not use”. She added.

South-africa , Nigeria , United-kingdom , Abuja , Abuja-federal-capital-territory , Ethiopia , Ghana , Mojisola-adeyeye , Vaccine-committee , Ministry-of-health , Melinda-gates-foundation , Agency-drug-registration

OECD Report on Nanomaterials and Nano-Enabled Products

Legal Disclaimer
You are responsible for reading, understanding and agreeing to the National Law Review's (NLR’s) and the National Law Forum LLC's Terms of Use and Privacy Policy before using the National Law Review website. The National Law Review is a free to use, no-log in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only. Any legal analysis, legislative updates or other content and links should not be construed as legal or professional advice or a substitute for such advice. No attorney-client or confidential relationship is formed by the transmission of information between you and the National Law Review website or any of the law firms, attorneys or other professionals or organizations who include content on the National Law Review website. If you require legal or professional advice, kindly contact an attorney or other suitable professional advisor.

Organization-for-economic-cooperation , Economic-cooperation , Moving-towards , Innovation-approach , More-sustainable-nanomaterials , Executive-summary , Regulatory-preparedness , Legal , Government , Oecd , Nano-enabled-products

Nanotechnology Now - OECD Publishes Report on Moving toward a Safe(r) Innovation Approach for More Sustainable Nanomaterials and Nano-Enabled Products

Nanotechnology Now - OECD Publishes Report on Moving toward a Safe(r) Innovation Approach for More Sustainable Nanomaterials and Nano-Enabled Products
nanotech-now.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nanotech-now.com Daily Mail and Mail on Sunday newspapers.

Lynnl-bergeson , Bergeson-campbell , Organization-for-economic-cooperation , Nanotechnology-columns , Innovation-approach , More-sustainable-nanomaterials , Economic-cooperation , Moving-towards , Executive-summary , Regulatory-preparedness , பெர்கெசோங்-கேம்ப்பெல் , ஆர்கநைஸேஶந்-க்கு-பொருளாதார-ஒத்துழைப்பு

OECD Publishes Report on Moving toward a Safe(r) Innovation Approach for More Sustainable Nanomaterials and Nano-Enabled Products | Bergeson & Campbell, P.C.

The Organization for Economic Cooperation and Development (OECD) published a report entitled
Moving Towards a Safe(r) Innovation Approach (SIA) for More Sustainable Nanomaterials and Nano-enabled Products. According to the Executive Summary, the report “presents common working descriptions to ensure a common understanding of concepts such as: Safe(r) Innovation Approach and its elements, Safe(r)-by-Design and Regulatory Preparedness.” The report compiles existing risk assessment tools, frameworks, and initiatives developed for Safe(r)-by-Design. OECD states that the inventory of risk assessment tools and frameworks should help industry implement a “Safe(r) Innovation Approach” for nanomaterials and nano-enabled products. This includes a review of lessons learned from applying existing Safe(r)-by-Design concepts and tools and methods applied in hazard, exposure, and risk assessment and management along the innovation value chain. OECD conducted a review of the applicability of the Safe(r)-by-Design concept, based on feedback gained through case studies and existing initiatives, and analyzed the constraints and limitations on the applicability of these tools and frameworks. The information is complemented by an inventory of regulatory strategies for raising awareness and improving decision-making, including foresight, horizon scanning, and other methodologies, and of available governance models that incorporate a Safe(r) Innovation Approach and Safe(r)-by-Design concept. The report also outlines the constraints and limitations on the applicability of these strategies and governance models. Finally, the report compiles information on regulatory initiatives related to the review of innovative approaches and technologies, assessing whether these concepts are already integrated into current legislation or guidance. The report proposes a combination of Safe(r)-by-Design and relevant regulatory strategies for awareness raising and decision making to achieve a Safe(r) Innovation Approach, supporting industrial initiatives in adopting a Safe(r) Innovation Approach with descriptors for a Safe(r) Innovation Approach for nanomaterials and nano-enabled products.

Bergeson-campbell , Organization-for-economic-cooperation , Economic-cooperation , Moving-towards , Innovation-approach , More-sustainable-nanomaterials , Executive-summary , Regulatory-preparedness , பெர்கெசோங்-கேம்ப்பெல் , ஆர்கநைஸேஶந்-க்கு-பொருளாதார-ஒத்துழைப்பு , பொருளாதார-ஒத்துழைப்பு , நகரும்-நோக்கி

Covid is here to stay

By Dr R Neerunjun Gopee
Among the decisions taken by Cabinet during its meeting on Friday 18
th are those about the ongoing Covid problem. It was to be expected that in light of the advent of vaccines that have been announced in the UK and the US, there would be some local development in this regard. In fact, we learn that ‘Cabinet has agreed to the setting up of a Special Fund to finance the National Covid-19 Vaccination Programme in the Republic of Mauritius. The Special Fund would be set up, under the Finance and Audit Act to mobilise and manage the funds required for implementing the Programme’.

Mauritius , United-kingdom , Germany , India , Italy , France , Reunion , London , City-of , Republic-of-mauritius , Prime-minister , R-neerunjun-gopee

Coronavirus: Mauritius sets up Special Fund to finance National COVID-19 Vaccination Programme

Port-Louis, Dec. 19, 2020 Mauritius will set up a special fund to mobilise and manage the funds required for implementing the National COVID-19 Vaccination Programme, the Government announced on Friday, following the weekly meeting of the Cabinet in Port-Louis.
To that effect, it said in a communiqué, the Ministry of Health and Wellness has prepared a COVID-19 Vaccination Preparation Plan in line with WHO Guidance that looks into various issues and implications, namely – (a) Regulatory Preparedness; (b) Planning and Coordination; (c) Costing and Funding; (d) Target Population; (e) Delivery Strategies; (f) Supply Chain and Healthcare Waste Management; (g) Human Resource Management and training; (h) Vaccines Acceptance and Uptake; (i) Safety Monitoring; (j) Immunisation and Monitoring Systems; (k) COVID-19 surveillance; and (l) Evaluation of COVID-19 Vaccine introduction.

Mauritius , Japan , Prime-minister , Ministry-of-health , Vaccination-programme , Preparation-plan , Regulatory-preparedness , Target-population , Delivery-strategies , Supply-chain , Healthcare-waste-management , Human-resource-management

Now that COVID-19 vaccines are out

Now that COVID-19 vaccines are out
Published 20 December 2020
THE United Kingdom became the first Western nation to begin mass vaccination against the coronavirus disease with 90-year-old pensioner, Margaret Keenan, the first person to receive the vaccine outside of clinical trials. It was a major step in the journey to kick out the pandemic, which has killed more than 1.66 million people worldwide. At least 74.95 million people have contracted the virus, though the number of cases is believed to be much higher than that.
There are currently more than 50 COVID-19 vaccine candidates in trials. The United States’ Centre for Disease Control says as of November 24, 2020, large-scale (Phase 3) clinical trials are in progress or being planned for three COVID-19 vaccines in the country (AstraZeneca’s COVID-19, Janssen’s COVID-19 and Moderna’s COVID-19). The UK government had since July signed deals for 90 million doses of promising coronavirus vaccines being developed – 30 million doses of the BioNtech/Pfizer vaccine and 60 million doses of Valneva vaccine. That is apart from 100 million doses of another vaccine being developed by AstraZeneca at the University of Oxford. The country had received 800,000 doses by December 8, enough to vaccinate 400,000 people, specifically those who are most at risk, including patients over 80 years old.

United-states , Nigeria , United-kingdom , Nigerian , Americans , British , Joseph-biden , Margaret-keenan , Tony-blair , Muhammadu-buhari , Osagie-ehanire , Biovaccine-nigeria-ltd

Décisions du Conseil des Ministres du 18 décembre2020

Maurice Info
Search
Les membres du gouvernement ont pris note de la création d’un of a Special Fund to finance the National COVID-19 Vaccination Programme, que la prérode de la quarantaine a été étendue au 15 février 2020, qu’il y a 24 cas de Covid-19 actifs dans les services hopsitlaier entre autres.
1. Cabinet has agreed to the setting up of a Special Fund to finance the National COVID-19 Vaccination Programme in the Republic of Mauritius. The Special Fund would be set up, under the Finance and Audit Act to mobilise and manage the funds required for implementing the Programme.

Germany , Roche-bois , Pamplemousses , Mauritius , Japan , Ile-aux-aigrettes , Grand-port , Flacq , Saudi-arabia , Solferino , Plaines-wilhems , Ile-des-deux-cocos